Welcome to the Future of Cancer Treatment with Molecular Partners and Orano Med

Zurich-Schlieren, Switzerland and Concord, Mass. – Oct. 22, 2024

Exciting Collaboration in Cancer Treatment Development

Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the strengthening of a previously announced co-development agreement with Orano Med, a clinical-stage radiopharmaceutical company developing targeted alpha therapies with lead-212 (212Pb). Both companies will develop and market 212Pb-based Radio-DARPin Therapeutics for the treatment of cancer.

This collaboration represents a significant advancement in the field of cancer treatment, offering new hope for patients around the world. By combining Molecular Partners’ expertise in DARPin therapeutics with Orano Med’s innovative approach to targeted alpha therapies, the two companies aim to revolutionize the way cancer is treated.

Radio-DARPin Therapeutics hold great promise for the future of cancer treatment. By targeting cancer cells with precision, these therapies have the potential to deliver more effective and less toxic treatment options for patients. The collaboration between Molecular Partners and Orano Med marks a crucial step towards bringing these cutting-edge therapies to market and improving outcomes for cancer patients.

How This Collaboration Will Impact You

As a patient, this collaboration could potentially offer you access to groundbreaking cancer treatments that are more targeted and less toxic than traditional therapies. Radio-DARPin Therapeutics have the potential to revolutionize the way cancer is treated, offering new hope for improved outcomes and quality of life.

How This Collaboration Will Impact the World

The collaboration between Molecular Partners and Orano Med has the potential to have a significant impact on the world of cancer treatment. By developing and marketing Radio-DARPin Therapeutics, the two companies are paving the way for a new class of precision therapies that could transform the standard of care for cancer patients worldwide. This collaboration represents a major step forward in the fight against cancer and offers hope for better outcomes for patients everywhere.

Conclusion

The collaboration between Molecular Partners and Orano Med in developing 212Pb-based Radio-DARPin Therapeutics holds great promise for the future of cancer treatment. By combining their expertise and innovative approaches, the two companies are working towards bringing cutting-edge therapies to market that could revolutionize the way cancer is treated. This collaboration represents a significant advancement in the field of cancer treatment and offers new hope for patients worldwide.